Nomination Committee appointed for the 2024 Annual General Meeting of Redsense Medical AB
A Nomination Committee has been established for the 2024 Annual General Meeting of Redsense Medical AB.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on May 9, 2023, consists of:
Patrik Byhmer, appointed by Seventh Sense Adventures Holding AB
Johannes Köpple, appointed by ShapeQ GmbH
Oscar Bergman, appointed by Swedbank Robur Fonder
Patrik Byhmer, Chairman of the Board, is the convener of the Nomination Committee
The Nomination Committee's task is to submit proposals to the Annual General Meeting regarding; Election of Chairman of the Meeting, number of Board members, election of Chairman of the Board and other members of the Board, fees to the Board of Directors and, where applicable, remuneration for committee work divided between each Board member, proposal for election of auditor and auditor's fees and, to the extent deemed necessary, proposal for amendments to the current instruction for the Nomination Committee.
Shareholders who wish to submit proposals to the company's Nomination Committee may do so by e-mail to patrik.byhmer@redsensemedical.com no later than January 10, 2024.
The Nomination Committee's proposals will be presented in the notice to the Annual General Meeting 2024 and on the company's website; www.redsensemedical.com
The Annual General Meeting will be held on May 8, 2024, in Halmstad.
Contact information
For more information, please contact:
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.